371 related articles for article (PubMed ID: 28526959)
21. The effects of adjuvant endocrine therapy on bone health in women with breast cancer.
Ramchand SK; Cheung YM; Yeo B; Grossmann M
J Endocrinol; 2019 Jun; 241(3):R111-R124. PubMed ID: 30991355
[TBL] [Abstract][Full Text] [Related]
22. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
[TBL] [Abstract][Full Text] [Related]
23. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Singh Ranger G
J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
[TBL] [Abstract][Full Text] [Related]
24. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
25. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
[TBL] [Abstract][Full Text] [Related]
26. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
27. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant aromatase inhibitor therapy in patients with stage I breast cancer at a regional oncology center in Israel: implementation of a 'switching' policy in postmenopausal patients after initial tamoxifen.
Geffen DB; Tokar M; Abu-Ghanem S; Braunstein R; Koretz M; Amir N; Delgado B; Sion-Vardi N; Ariad S; Lazarev I
Oncology; 2013; 85(3):145-52. PubMed ID: 23988814
[TBL] [Abstract][Full Text] [Related]
29. Breast cancer adjuvant endocrine therapy.
Cigler T; Goss PE
Cancer J; 2007; 13(3):148-55. PubMed ID: 17620763
[TBL] [Abstract][Full Text] [Related]
30. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.
Baumgart J; Nilsson K; Stavreus Evers A; Kunovac Kallak T; Kushnir MM; Bergquist J; Sundström Poromaa I
Climacteric; 2014 Feb; 17(1):48-54. PubMed ID: 23647561
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.
Harper-Wynne CL; Sacks NP; Shenton K; MacNeill FA; Sauven P; Laidlaw IJ; Rayter Z; Miall S; Howes A; Salter J; Hills MJ; Lowe FM; A'Hern R; Nasiri N; Doody D; Iqbal J; Dowsett M
J Clin Oncol; 2002 Feb; 20(4):1026-35. PubMed ID: 11844826
[TBL] [Abstract][Full Text] [Related]
32. Implications of first-line adjuvant treatment with aromatase inhibitors in recurrent metastatic breast cancer.
Sokolowicz LE; Gradishar WJ
Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S24-30. PubMed ID: 15347436
[TBL] [Abstract][Full Text] [Related]
33. [Current adjuvant endocrine treatment of breast cancer].
Dedes KJ; Gabriel N; Fink D
Gynakol Geburtshilfliche Rundsch; 2008; 48(3):130-7. PubMed ID: 18566529
[TBL] [Abstract][Full Text] [Related]
34. Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease.
Polyzos SA; Anastasilakis AD; Kountouras J; Makras P; Papatheodorou A; Kokkoris P; Sakellariou GT; Terpos E
J Bone Miner Metab; 2016 Jul; 34(4):447-56. PubMed ID: 26056025
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
36. Sclerostin rather than Dickkopf-1 is associated with mSASSS but not with disease activity score in patients with ankylosing spondylitis.
Sun W; Tian L; Jiang L; Zhang S; Zhou M; Zhu J; Xue J
Clin Rheumatol; 2019 Apr; 38(4):989-995. PubMed ID: 30443790
[TBL] [Abstract][Full Text] [Related]
37. Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen.
Smith IE
Breast; 2004 Dec; 13 Suppl 1():S3-9. PubMed ID: 15585377
[TBL] [Abstract][Full Text] [Related]
38. Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence.
Montemurro F; Del Mastro L; De Laurentiis M; Puglisi F
Expert Rev Anticancer Ther; 2016; 16(2):211-8. PubMed ID: 26634955
[TBL] [Abstract][Full Text] [Related]
39. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
40. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
Spicer J; Ellis P
Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
